Notice2025-14345
Arthritis Advisory Committee; Termination
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 30, 2025
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or the Agency) is announcing the termination of the Agency's Arthritis Advisory Committee (Committee) by the Commissioner of Food and Drugs (Commissioner). The Commissioner has determined that it is not necessary to continue to maintain this Committee.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 144 (Wednesday, July 30, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 144 (Wednesday, July 30, 2025)]
[Notices]
[Pages 35876-35877]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-14345]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2025-N-0008]
Arthritis Advisory Committee; Termination
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the termination of the Agency's Arthritis Advisory Committee
(Committee) by the Commissioner of Food and Drugs (Commissioner). The
Commissioner has determined that it is not necessary to continue to
maintain this Committee.
DATES: This Committee will terminate on the date of publication of this
notice.
FOR FURTHER INFORMATION CONTACT: Emily Helms Williams, Director,
Advisory Committee Oversight and Management Staff, Office of the Chief
Scientist, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 1, Rm. 3240, Silver Spring, MD 20993, 301-796-3381,
<a href="/cdn-cgi/l/email-protection#51143c383d287f19343d3c2206383d3d38303c22113735307f3939227f363e27"><span class="__cf_email__" data-cfemail="c287afabaebbec8aa7aeafb195abaeaeaba3afb182a4a6a3ecaaaab1eca5adb4">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The Arthritis Advisory Committee was
established on April 5, 1974 (39 FR 14737-14738), to advise the
Commissioner or designee in discharging responsibilities as they relate
to helping to ensure safe and effective drugs for human use in
arthritic conditions, and as required, any other product for which FDA
has regulatory responsibility. This Committee has met infrequently in
recent years, and FDA has determined that the effort and expense of
[[Page 35877]]
maintaining the Committee is no longer justified. This Committee is
therefore terminated, effective on July 30, 2025, in accordance with 21
CFR 14.55. This notice is issued under the Federal Advisory Committee
Act of October 6, 1972 (Pub. L. 92-463) (5 U.S.C. 1001 et seq.).
Elsewhere in this issue of the Federal Register, FDA is publishing a
final rule announcing the removal of the Arthritis Advisory Committee
from the Agency's list of standing advisory committees.
Dated: July 25, 2025.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2025-14345 Filed 7-29-25; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 30, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.